These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 20627935)

  • 1. Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse.
    Reiniger N; Lau K; McCalla D; Eby B; Cheng B; Lu Y; Qu W; Quadri N; Ananthakrishnan R; Furmansky M; Rosario R; Song F; Rai V; Weinberg A; Friedman R; Ramasamy R; D'Agati V; Schmidt AM
    Diabetes; 2010 Aug; 59(8):2043-54. PubMed ID: 20627935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletion of the formin Diaph1 protects from structural and functional abnormalities in the murine diabetic kidney.
    Manigrasso MB; Friedman RA; Ramasamy R; D'Agati V; Schmidt AM
    Am J Physiol Renal Physiol; 2018 Dec; 315(6):F1601-F1612. PubMed ID: 30132346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy.
    Wendt TM; Tanji N; Guo J; Kislinger TR; Qu W; Lu Y; Bucciarelli LG; Rong LL; Moser B; Markowitz GS; Stein G; Bierhaus A; Liliensiek B; Arnold B; Nawroth PP; Stern DM; D'Agati VD; Schmidt AM
    Am J Pathol; 2003 Apr; 162(4):1123-37. PubMed ID: 12651605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease.
    Tanji N; Markowitz GS; Fu C; Kislinger T; Taguchi A; Pischetsrieder M; Stern D; Schmidt AM; D'Agati VD
    J Am Soc Nephrol; 2000 Sep; 11(9):1656-1666. PubMed ID: 10966490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteomeles schwerinae extracts inhibits the binding to receptors of advanced glycation end products and TGF-β1 expression in mesangial cells under diabetic conditions.
    Kim YS; Jung DH; Lee IS; Pyun BJ; Kim JS
    Phytomedicine; 2016 Apr; 23(4):388-97. PubMed ID: 27002409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin.
    Myint KM; Yamamoto Y; Doi T; Kato I; Harashima A; Yonekura H; Watanabe T; Shinohara H; Takeuchi M; Tsuneyama K; Hashimoto N; Asano M; Takasawa S; Okamoto H; Yamamoto H
    Diabetes; 2006 Sep; 55(9):2510-22. PubMed ID: 16936199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice.
    Yamamoto Y; Kato I; Doi T; Yonekura H; Ohashi S; Takeuchi M; Watanabe T; Yamagishi S; Sakurai S; Takasawa S; Okamoto H; Yamamoto H
    J Clin Invest; 2001 Jul; 108(2):261-8. PubMed ID: 11457879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice.
    Watson AM; Gray SP; Jiaze L; Soro-Paavonen A; Wong B; Cooper ME; Bierhaus A; Pickering R; Tikellis C; Tsorotes D; Thomas MC; Jandeleit-Dahm KA
    Diabetes; 2012 Aug; 61(8):2105-13. PubMed ID: 22698914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy.
    Tan AL; Sourris KC; Harcourt BE; Thallas-Bonke V; Penfold S; Andrikopoulos S; Thomas MC; O'Brien RC; Bierhaus A; Cooper ME; Forbes JM; Coughlan MT
    Am J Physiol Renal Physiol; 2010 Mar; 298(3):F763-70. PubMed ID: 20015941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.
    Ziyadeh FN; Hoffman BB; Han DC; Iglesias-De La Cruz MC; Hong SW; Isono M; Chen S; McGowan TA; Sharma K
    Proc Natl Acad Sci U S A; 2000 Jul; 97(14):8015-20. PubMed ID: 10859350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency.
    Wolf G; Schanze A; Stahl RA; Shankland SJ; Amann K
    Kidney Int; 2005 Oct; 68(4):1583-9. PubMed ID: 16164635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy.
    Wendt T; Tanji N; Guo J; Hudson BI; Bierhaus A; Ramasamy R; Arnold B; Nawroth PP; Yan SF; D'Agati V; Schmidt AM
    J Am Soc Nephrol; 2003 May; 14(5):1383-95. PubMed ID: 12707408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between the expression of advanced glycation end-products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy.
    Suzuki D; Toyoda M; Yamamoto N; Miyauchi M; Katoh M; Kimura M; Maruyama M; Honma M; Umezono T; Yagame M
    Intern Med; 2006; 45(7):435-41. PubMed ID: 16679697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.
    Hou B; Qiang G; Zhao Y; Yang X; Chen X; Yan Y; Wang X; Liu C; Zhang L; Du G
    Cell Physiol Biochem; 2017; 44(6):2378-2394. PubMed ID: 29262395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of late-stage diabetic nephropathy in OVE26 diabetic mice.
    Zheng S; Noonan WT; Metreveli NS; Coventry S; Kralik PM; Carlson EC; Epstein PN
    Diabetes; 2004 Dec; 53(12):3248-57. PubMed ID: 15561957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of the receptor for advanced glycation end products (RAGE) -374 T/A gene polymorphism and circulating soluble RAGE with nephropathy in type 1 diabetic patients.
    Abdel-Azeez HA; El-Okely AM
    Egypt J Immunol; 2009; 16(1):95-106. PubMed ID: 20726326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy.
    Cohen MP; Sharma K; Jin Y; Hud E; Wu VY; Tomaszewski J; Ziyadeh FN
    J Clin Invest; 1995 May; 95(5):2338-45. PubMed ID: 7738197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting albumin glycation ameliorates diabetic nephropathy in the db/db mouse.
    Cohen MP; Masson N; Hud E; Ziyadeh F; Han DC; Clements RS
    Exp Nephrol; 2000; 8(3):135-43. PubMed ID: 10810230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletion of bone-marrow-derived receptor for AGEs (RAGE) improves renal function in an experimental mouse model of diabetes.
    Tesch G; Sourris KC; Summers SA; McCarthy D; Ward MS; Borg DJ; Gallo LA; Fotheringham AK; Pettit AR; Yap FY; Harcourt BE; Tan AL; Kausman JY; Nikolic-Paterson D; Kitching AR; Forbes JM
    Diabetologia; 2014 Sep; 57(9):1977-85. PubMed ID: 24957662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor.
    Sourris KC; Morley AL; Koitka A; Samuel P; Coughlan MT; Penfold SA; Thomas MC; Bierhaus A; Nawroth PP; Yamamoto H; Allen TJ; Walther T; Hussain T; Cooper ME; Forbes JM
    Diabetologia; 2010 Nov; 53(11):2442-51. PubMed ID: 20631980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.